Carboplatin + Gemcitabine + Bevacizumab (platinum-sensitive recurrent ovarian, OCEANS regimen)

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Components	`DRUG-CARBOPLATIN` `DRUG-GEMCITABINE` `DRUG-BEVACIZUMAB`

ID	`REG-CARBO-GEM-BEV-OVARIAN`
Type	Regimen
Status	reviewed 2026-04-27 \| pending_clinical_signoff
Diseases	None declared
Sources	`SRC-ESMO-OVARIAN-2024` `SRC-NCCN-OVARIAN-2025` `SRC-OCEANS-AGHAJANIAN-2012`

Notes

OCEANS regimen — primary platinum-sensitive 2L regimen with strongest carbo+gem+bev RCT evidence. PFS 12.4 vs 8.4 mo (HR 0.484) over carbo+gem alone. OS not improved (33.3 vs 32.9 mo). Preferred over carbo+PLD+bev in UA per access (PLD often OOP). Day-8 gemcitabine commonly held for thrombocytopenia — acceptable; protocol tolerates dose reductions.

Used By

Indication

IND-OVARIAN-2L-PLAT-SENS-CARBO-GEM-BEV - IND-OVARIAN-2L-PLAT-SENS-CARBO-GEM-BEV
IND-OVARIAN-2L-PLAT-SENS-CARBO-PLD-BEV - IND-OVARIAN-2L-PLAT-SENS-CARBO-PLD-BEV

Regimen

REG-CARBO-PLD-BEV-OVARIAN - Carboplatin + PLD + Bevacizumab (platinum-sensitive recurrent ovarian)